alpha GPC -- Glycerylphosphorylcholine * Supports Cognitive Function

references:

Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction, Science. 1982;217:408-414. 2. Larson EB, Kukull WA, Katzman RL. Cognitive impairment: Dementia and Alzheimer's disease. Annu Rev Public Health. 1992;13:431-449. 3. Hofman A, Rocca WA, Brayne C, et al, for the European Prevalence Research Group. The prevalence of dementia in Europe: A collaborative study of 1980-1990 findings. Int d Epidemiol. 1991;20:736-748. 4. Blackwood W, Corsellis JAN, eds. Greenfield's Neuropathology. 3rd ed. London: Arnold; 1976. 5. Geldmacher DS. Cost-effective recognition and diagnosis of dementia. 5emin Neurol. 2002;22:63-70. 6. Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ. 1978;2:1457-1459. 7. Perry EK. The cholinergic hypothesis--ten years on. Br Med Bull. 1986;42:63-69. 8. Giacobini E. From molecular structure to Alzheimer therapy. Jpn d Pharmacol. 1997;74:225-241. 9. Giacobini E. Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: From tacrine to future applications. Neurochem Int. 1998;32:413-419. 10. Brinkman SD, Smith RC, Meyer JS, et al. Lecithin and memory training in suspected Alzheimer's disease. J Gerontol. 1982;37:4-9. 11. Davis E, Emmerling MR, Jaen JC, et al. Therapeutic intervention in dementia. Crit Rev Neurobiol. 1993;7:41-83. 12. Amenta E Parnetti L, Gallai V, Wallin A. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropiate approaches? Mech Ageing Dev. 2001;122:2025-2040. 13. Sigala S, Imperato A, Rizzonelli P, et al. k-Alpha-glycerylphosphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat. Eurd Pharmacol. 1992;211:351-358. 14. Govoni S, Battaini E Lucchi L, et al. Effects of alpha-glycerylphosphorylcholine in counteracting drug-induced amnesia: Through cholinergic and non-cholinergic mechanisms [in Italian]. Basi Raz Ter. 1991;21:75-78. 15. Canonico PL, Nicoletti F, Scapagnini U. Neurochemical and behavioral effects of alpha-glycerylphosphorylcholine [in Italian]. Basi Raz Te~ 1990;20: 53-54. 191 CLINICAL THERAPEUTICS ® 16. Parnetti L, Amenta E Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: An analysis of published clinical data. Mech Ageing Dev. 2001;122:2041-2055. 17. Venn RD. The Sandoz Clinical Assessment-Geriatric (SCAG) scale. A general-purpose psychogeriatric rating scale. Gerontology. 1983;29:185-198. 18. Di Perri R, Coppola G, Ambrosio LA, et al. A multicentre trial to evaluate the efficacy and tolerability of alpha-glycerylphosphorylcholine versus cytosine diphosphocholine in patients with vascular dementia. J Int Med Res. 1991;19:330-341. 19. Frattola L, Piolti R, Bassi S, et al. Multicenter clinical comparison of the effects of choline alphoscerate and cytidine diphosphocholine in the treatment of multi-infarct dementia. Curt Ther Res Clin Exp. 1991;49:683-693. 20. Muratorio A, Bonuccelli U, Nuti A, et al. A neurotropic approach to the treatment of multi-infarct dementia using L-c~-glycerylphosphorylcholine. Curt Ther Res Clin Exp. 1992;52:741-75l. 21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: APA; 1994. 22. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944. 23. Folstein ME Folstein SE. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198. 24. Loeb C, Gandolfo C. Diagnostic evaluation of degenerative and vascular dementia. Stroke. 1983;14:399-401. 25. Hamilton M. A rating scale for depression.J Neurol Neurosurg Psychiatry. 1960;23:56-62. 26. Hamilton M. Development of a rating scale for primary depressive illness. BrJ Soc Clin Psych& 1967;6:278-296. 27. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. AmJ Psychiatry. 1984;141:1356-1364. 28. Reisberg B, Ferris SH, De Leon MJ, et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139:1136-1139. 29. National Institute of Mental Health. Clinical global impressions. In: Guy W, ed. ECDEU Assessment for Psychopharmacology. Revised edition. Rockville, Md: National Institute of Mental Health; 1976:217-222. 30. Burns A, Russell E, Page S. New drugs for Alzheimer's disease. Br J Psychiatry. 1999;174:476-479. 31. Kumar V, Anand R, Messina J, et al. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol. 2000;7:159-169. 32. Knapp MJ, Knopman DS, Solomon PR, et al, for the Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 1994;271:985-991. 192 M. Moreno 33. Lindstrom MJ, Bates DM. Newton-Rapshon algorithms for linear-mixed effects models for repeated measure data. J Am Stat Assoc. 1998;83:1014-1022. 34. Thai LJ, Carta A, Clarke WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology 1996;47:705-711. 35. Rogers SL, Friedhoff LT, for the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 1996;7:293-303. 36. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, for the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Arch Intern Med. 1998; 158:1021-1031. 37. Corey-Bloom J, Anand R, Veach J, for the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and the safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998;1:55-65. 38. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ. 1999;318: 633-638. 39. Amenta E Bronzetti E, Del Valle M, Vega JA. Effects of alpha-glycerylphosphorylcholine in neuroanatomy of aging brain in experimental animals [in Italian]. Basi Raz Te~: 1990;20:31-38. Address correspondence to: Scientific Department, Italfarmaco SpA, via dei Lavoratori 54, 20092 Cinisello Balsamo, Milan, Italy.

• Deep Thought 60ct